Malaysian Genomics Resource
Malaysian Genomics Resource Centre Berhad, together with its subsidiaries, provides genetics, genomics, immunotherapy, and biopharmaceutical services worldwide. Its flagship product, Dtect genetic screening tests which inspects DNA for markers associated with genetic variations that influence various biological processes. The company also offers genome sequencing services for humans, animals, pla… Read more
Malaysian Genomics Resource (0155) - Total Liabilities
Latest total liabilities as of September 2025: RM3.27 Million MYR
Based on the latest financial reports, Malaysian Genomics Resource (0155) has total liabilities worth RM3.27 Million MYR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Malaysian Genomics Resource - Total Liabilities Trend (2015–2025)
This chart illustrates how Malaysian Genomics Resource's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Malaysian Genomics Resource Competitors by Total Liabilities
The table below lists competitors of Malaysian Genomics Resource ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bubalus Resources Ltd
AU:BUS
|
Australia | AU$122.42K |
|
STORE ELECTRONIC
BE:S4M
|
Germany | €775.00 Million |
|
Choppies Enterprises Ltd
JSE:CHP
|
South Africa | ZAC2.71 Billion |
|
Magontec Ltd
AU:MGL
|
Australia | AU$25.07 Million |
|
Financiere Marjos SA
PA:FINM
|
France | €1.17 Million |
|
Thai Poly Acrylic Public Company Limited
BK:TPA
|
Thailand | ฿167.45 Million |
|
Visionstate Corp
PINK:VSSSF
|
USA | $505.55K |
|
Castle Minerals Ltd
AU:CDT
|
Australia | AU$1.23 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Malaysian Genomics Resource's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Malaysian Genomics Resource's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Malaysian Genomics Resource (2015–2025)
The table below shows the annual total liabilities of Malaysian Genomics Resource from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | RM4.20 Million | +25.12% |
| 2024-06-30 | RM3.36 Million | -17.81% |
| 2023-06-30 | RM4.08 Million | -15.67% |
| 2022-06-30 | RM4.84 Million | -0.20% |
| 2021-06-30 | RM4.85 Million | +486.11% |
| 2020-06-30 | RM827.98K | -96.07% |
| 2019-06-30 | RM21.07 Million | +0.01% |
| 2018-06-30 | RM21.07 Million | +56.14% |
| 2017-06-30 | RM13.49 Million | +550.16% |
| 2016-06-30 | RM2.08 Million | -48.95% |
| 2015-06-30 | RM4.07 Million | -- |